TY - JOUR T1 - Aerosol generation in children undergoing high flow nasal cannula therapy JF - medRxiv DO - 10.1101/2020.12.10.20245662 SP - 2020.12.10.20245662 AU - Elliott T. Gall AU - Aurélie Laguerre AU - Michelle Noelck AU - Annalise Van Meurs AU - Jared A Austin AU - Byron A. Foster Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/12/14/2020.12.10.20245662.abstract N2 - Objective High flow nasal cannula therapy (HFNC) may increase aerosol generation, putting health care workers at increased risk of infection, including from SARS-CoV-2. This study examined whether use of HFNC increases near-field aerosols and if there is a relationship between flow rate and near-field aerosol concentrations.Patients and Methods Subjects between 30 days and 2 years of age were enrolled. Each child received HFNC therapy at different flow rates over time. Three sampling stations with particle counters were deployed to measure aerosol generation and dispersion in the room: station one within 0.5 m of the subject, station two at 2 m, and station three on the other side of the room. We also measured carbon dioxide (CO2) and relative humidity. Station three (far-field) measurements were used to adjust the station one (near-field) measurements for room conditions.Results We enrolled ten children ranging from 6-24 months (median 9 months), two with respiratory illness. Elevated CO2 indicated the near-field measurements were in the breathing plane of the subjects. Near-field breathing plane concentrations of aerosols with diameter 0.3 – 10 µm are elevated by the presence of the patient with no HFNC flow, relative to the room far-field, by 0.45 #/cm3. While we observed variability between subjects in their emission and dispersion of particles, we did not find an association between HFNC and near-field elevations of particle counts.Conclusion Near-patient levels of particles with diameter in the 0.3-10 µm range was not affected by the use of HFNC in healthy patients. Further study on older children and children with increased mucus production may be warranted.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Doernbecher Philanthropy Board provided funding for the study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Oregon Health & Science University IRB approved this study as human subjects research. All parents provided written consent to participate.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDeidentified individual participant data will not be made available. Measurements of constituents in air made in participant rooms will be made available upon reasonable request. ER -